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Introduction
Severity is a basic feature that defines the prognosis of a
disease. FMF presents with a variety of clinic and
laboratory manifestations affecting severity, and evalua-
tion of prognosis is an elusive task. Different severity
scores have been previously proposed for FMF, and
commonly used ones include Mor, Pras and Tel Hasho-
mer severity scores however recent studies showed that
there is no consistency among them.
Objectives
The aim of this study was to develop and validate a new
set of criteria for the assessment of disease severity for
FMF patients by a multicenter study.
Methods
Delphi survey technique was used for the initial phase of
the study. A panel of experts including twenty-four FMF
specialists from 16 countries participated in the survey.
The first Delphi round aimed to identify all clinical and
laboratory features considered to be associated with the
severity of FMF. In the second round, 33 structured ques-
tions were developed to collect expert opinions about
FMF severity. At the third and the last rounds, the expert
panel was asked to evaluate the answers given to the ques-
tions in the previous round. After all rounds, a subgroup
of the expert panel (ten experts and one facilitator) gath-
ered in a consensus meeting (NGT) on November 13,
2012 in Washington DC, USA. In this meeting, the results
of all previous rounds and items for the candidate criteria
and their standard definitions were discussed.
Results
In Delphi rounds, three of the mostly reported clinical
items were ‘response to colchicine treatment’, ‘frequency
of attacks’ and ‘presence of arthritis’ and laboratory para-
meters were high levels of Serum amyloid A (SAA),
C-reactive protein (CRP), and the MEFV gene mutations.
At the consensus meeting, items revealed through the
second and the third rounds were reevaluated, and the fol-
lowing nine items were selected for the final set of severity
criteria: presence of a chronic sequel (including amyloido-
sis, growth retardation, anemia, splenomegaly), organ
dysfunction (nephrotic-range proteinuria), organ failure
(cardiac, renal, thyroid etc.), frequency of attacks (average
number of attacks between 1-2 per months), increased
acute phase reactants (CRP, SAA, ESR, fibrinogen) during
the attack-free period (at least 2 weeks after the last attack
in 2 occasions one-month apart), involvement of more
than 2 sites during an individual acute attack (pericarditis,
pleuritis, peritonitis, synovitis), more than 2 different types
of attack during the course of the disease (isolated fever,
pericarditis, pleuritis, peritonitis, synovitis, erysipelas like
erythema, scrotal involvement, vaginitis, myalgia etc.),
duration of attacks (more than 72 hours in at least
3 attacks during one year), effort-induced leg pain (pain
following standing or excercising, excluding other causes).
Conclusion
The panel of experts agreed on the nine items to be used
in the severity criteria for FMF, and results of the valida-
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